BITBIOME Trademark

Trademark Overview


On Thursday, July 25, 2019, a trademark application was filed for BITBIOME with the United States Patent and Trademark Office. The USPTO has given the BITBIOME trademark a serial number of 79275265. The federal status of this trademark filing is REGISTERED as of Tuesday, March 16, 2021. This trademark is owned by bitBiome, Inc.. The BITBIOME trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, and biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cys...

Medical screening; providing information relating to medical services; genetic testing for medical purposes

Structural and functional analysis of genomes; research and development in the field of microorganisms and cells for the healthcare, scientific, biochemical, pharmaceutical, medical, agricultural, food, cosmetic, animal health, diagnostic, chemical, bioremediation, sanitation, oral care, and oil industries; pharmaceutical research and development; pharmaceutical product evaluation services; medical research; medical laboratory services; genetic testing for scientific research purposes
bitbiome

General Information


Serial Number79275265
Word MarkBITBIOME
Filing DateThursday, July 25, 2019
Status700 - REGISTERED
Status DateTuesday, March 16, 2021
Registration Number6291515
Registration DateTuesday, March 16, 2021
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, December 29, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, and biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical biological preparations for medical purposes for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical preparations for human use, namely, analgesics, antibiotics, anti-fungals, anti-infective preparations, anti-virals, anti-parasitics, and cytokine inhibitory drugs; human growth hormones, immunosuppressants, immunotherapies for the treatment of cancer, medicated dermatological preparations, pharmaceutical antibodies for disease testing, diagnosis, and treatment purposes, pharmaceutical preparations that modulate the immune system, pharmaceutical and biological preparations for immunotherapy, including T Cell therapy, sedatives, smoking cessation preparations, tranquillizers, vaccines for human use, and vitamins; and preparations for destroying vermin, fungicides, herbicides
Pseudo MarkBIT BIOME
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesMedical screening; providing information relating to medical services; genetic testing for medical purposes
Goods and ServicesStructural and functional analysis of genomes; research and development in the field of microorganisms and cells for the healthcare, scientific, biochemical, pharmaceutical, medical, agricultural, food, cosmetic, animal health, diagnostic, chemical, bioremediation, sanitation, oral care, and oil industries; pharmaceutical research and development; pharmaceutical product evaluation services; medical research; medical laboratory services; genetic testing for scientific research purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 7, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 7, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, January 7, 2020
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamebitBiome, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTokyo 169-0051
JP

Party NamebitBiome, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTokyo 169-0051
JP

Party NamebitBiome, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTokyo 169-0051
JP

Trademark Events


Event DateEvent Description
Friday, January 19, 2024NEW REPRESENTATIVE AT IB RECEIVED
Sunday, July 11, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, June 17, 2021FINAL DISPOSITION NOTICE SENT TO IB
Thursday, June 17, 2021FINAL DISPOSITION PROCESSED
Wednesday, June 16, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, March 16, 2021REGISTERED-PRINCIPAL REGISTER
Sunday, January 10, 2021NOTIFICATION PROCESSED BY IB
Tuesday, December 29, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 29, 2020PUBLISHED FOR OPPOSITION
Wednesday, December 23, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, December 23, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, December 9, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 19, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 19, 2020EXAMINER'S AMENDMENT ENTERED
Thursday, November 12, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, November 12, 2020EXAMINERS AMENDMENT E-MAILED
Thursday, November 12, 2020EXAMINERS AMENDMENT -WRITTEN
Friday, August 28, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, August 28, 2020NON-FINAL ACTION E-MAILED
Friday, August 28, 2020NON-FINAL ACTION WRITTEN
Monday, August 24, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 24, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 24, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, August 21, 2020ASSIGNED TO LIE
Tuesday, August 4, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, July 10, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, July 10, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 10, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, July 10, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 10, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 10, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, February 28, 2020REFUSAL PROCESSED BY IB
Friday, February 7, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, February 7, 2020REFUSAL PROCESSED BY MPU
Saturday, January 11, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, January 11, 2020APPLICATION FILING RECEIPT MAILED
Friday, January 10, 2020NON-FINAL ACTION WRITTEN
Tuesday, January 7, 2020ASSIGNED TO EXAMINER
Tuesday, January 7, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 26, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB